Tempus AI Inc. has announced the launch of Paige Predict, a new suite of digital pathology applications designed to analyze H&E whole slide images and help inform testing decisions in cancer care. The AI-powered platform predicts the presence or absence of clinically relevant biomarkers from a single slide, aiding physicians even when tissue samples are limited. Built using Paige's foundation model and a combined dataset from both Tempus and Paige, Paige Predict leverages data from over 200,000 patients and covers 123 biomarkers across 16 cancer types. This launch follows Tempus's acquisition of Paige and represents an expansion of the company’s offerings in digital pathology and precision medicine.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tempus AI Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260121403553) on January 21, 2026, and is solely responsible for the information contained therein.